( , ) Good Practice Statement 2: , , ,
Magis D., Ambrosini A., Sandor P., Jacquy J., Laloux P., Schoenen J
Role of chemokines In recent years, chemokinessmall (810 kDa), soluble proteinshave been increasingly recognized for their role in the pathogenesis of AP, particularly through mediating inflammatory cell adhesion, integrin activation, and leukocyte transendothelial migration
Its long-acting platform may appeal to patients and payers if monthly or less frequent dosing can improve adherence while maintaining meaningful efficacy
The magnitude of weight change cannot be assumed to represent a precise estimate of adiposity loss and may partially reflect fluid shifts rather than true changes in body composition